{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-055462","form_type":"8-K","ticker":"TARA","cik":"0001359931","company_name":"Protara Therapeutics, Inc.","filed_at":"2026-05-13T12:05:18+00:00","discovered_at":"2026-05-13T12:10:00.353567+00:00","generated_at":"2026-05-13T12:20:07.329669+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Protara Therapeutics Reports Q1 2026 Results, Advances TARA-002 Programs in LMs and NMIBC","bullets":["Cash and cash equivalents and investments of $177.4 million as of March 31, 2026, expected to fund operations into 2028.","Net loss of $17.8 million ($0.31 per share) for Q1 2026, compared to $11.9 million loss in Q1 2025.","Intends to submit BLA for TARA-002 in Lymphatic Malformations in second half of 2027 based on STARBORN-1 trial.","Expects to complete enrollment of BCG-Unresponsive cohort in ADVANCED-2 trial and initiate ADVANCED-3 trial in BCG-Naïve patients in second half of 2026.","Updated interim safety and durability data from STARBORN-1 to be presented at ISSVA World Congress in May 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-055462","json":"https://secwatch.observer/filing/0001213900-26-055462.json","markdown":"https://secwatch.observer/filing/0001213900-26-055462.md","text":"https://secwatch.observer/filing/0001213900-26-055462.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1359931/000121390026055462/0001213900-26-055462-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1359931/000121390026055462/ea0288581-8k_protara.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-13T12:20:07.329669+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"320647bea8b0c0f14c6a9c6c3630733f3e42f726","claim":"Protara Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income $17.8 million, or $0.31 per share, EPS $0.31 per share.","evidence_excerpt":"For the first quarter of 2026, Protara incurred a net loss of $17.8 million, or $0.31 per share, compared with a net loss of $11.9 million, or $0.29 per share, for the same period in 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1359931/000121390026055462/0001213900-26-055462-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Net income","value":"$17.8 million, or $0.31 per share"},{"label":"EPS","value":"$0.31 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}